Foundation Resource Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-39,347
Closed -$6.75M 53
2024
Q2
$6.75M Sell
39,347
-290
-0.7% -$48K 1.08% 31
2024
Q1
$7.22M Sell
39,637
-46
-0.1% -$7.93K 1.13% 32
2023
Q4
$6.15M Sell
39,683
-251
-0.6% -$36.6K 0.98% 33
2023
Q3
$5.95M Sell
39,934
-512
-1% -$75.2K 0.99% 32
2023
Q2
$5.45M Sell
40,446
-6
-0% -$880 0.91% 33
2023
Q1
$6.45M Sell
40,452
-80
-0.2% -$12.2K 1.07% 31
2022
Q4
$6.55M Sell
40,532
-5
-0% -$767 1.08% 32
2022
Q3
$5.44M Sell
40,537
-20
-0% -$2.87K 1.03% 31
2022
Q2
$6.21M Sell
40,557
-80
-0.2% -$12.2K 1.11% 31
2022
Q1
$6.59M Sell
40,637
-64
-0.2% -$9.3K 1.02% 29
2021
Q4
$5.51M Sell
40,701
-410
-1% -$48.4K 1.07% 29
2021
Q3
$4.43M Sell
41,111
-200
-0.5% -$22.9K 1% 28
2021
Q2
$4.65M Hold
41,311
1.04% 27
2021
Q1
$4.47M Sell
41,311
-963
-2% -$103K 1.06% 27
2020
Q4
$4.53M Buy
42,274
+158
+0.4% +$15.2K 1.18% 28
2020
Q3
$3.69M Sell
42,116
-1,135
-3% -$107K 1.13% 26
2020
Q2
$4.25M Sell
43,251
-1,135
-3% -$99.9K 1.31% 25
2020
Q1
$3.38M Buy
+44,386
New +$3.78M 1.21% 26

Other funds holding ABBV

Foundation Resource Management's ABBV Position: Q3 2024 in Review

Foundation Resource Management sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 39,347 shares — an estimated $6.75M sold.

Foundation Resource Management first reported a position in ABBV in Q1 2020 and held it in 18 quarters. The position peaked at $7.22M in Q1 2024. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Foundation Resource Management reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Foundation Resource Management sold 39,347 AbbVie shares in Q3 2024, an estimated $6.75M.
  • Foundation Resource Management first reported a position in AbbVie in Q1 2020 and held it in 18 quarters.
  • Foundation Resource Management's AbbVie position peaked at $7.22M in Q1 2024.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Foundation Resource Management's 13F filing for Q3 2024, filed 10 Oct 2024.